Improving Tumor Oxygenation in Cervical Cancer

Cervical Cancer Clinical Trial

Official title:

Improving Tumor Oxygenation in Cervical Cancer With Methazolamide

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00257829
• Other study ID #: UCI 03-41
• Status: Withdrawn
• Phase: Phase 2
• Start date: July 2004
• Est. completion date: September 20, 2006

Study information

• Verified date: November 2018
• Source: University of California, Irvine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Phenomenon of Tumor Hypoxia Many solid tumors are relatively resistant to treatment with ionizing radiation and certain chemotherapeutic agents such as anthracyclines that are affected adversely by acidic pH. These effects have primarily been attributed to the presence of hypoxic cells within the tumor. The relevance of hypoxia with respect to failure of radiotherapy to cure certain malignancies has had a chequered history. However, in recent years the evidence that hypoxia plays a central role in relative radioresistance has become more compelling.

Since approximately two-thirds of all women suffering from cervical carcinoma receive radiation as a component of their therapy, an enhanced understanding of the interactions between hypoxia and radiation as a component of their therapy, an enhanced understanding of the interactions between hypoxia and radiation resistance is critical to improving outcome among those with cervical cancer.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 20, 2006
• Est. primary completion date: September 20, 2006
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The subject will have a malignant tumor of the cervix which is not curable by surgery in which it has been determined the subject is to receive the standard care of treatment of radiation therapy and chemotherapy.

• The subject must have adequate bone marrow function, renal function, hepatic function and neurologic function.

• The subject should be free of active infection requiring antibiotics.

• The subject must have signed the approved informed consent

• If the subject is of childbearing age, they must have a negative urine pregnancy test with effective contraception

• The subject must have met pre-entry requirements

1. Physical examination to include pelvic examination, blood counts, assessment of liver and kidney status through blood studies

2. A serum pregnancy test

3. Detectable tumor will be measured.

Exclusion Criteria:

• The subject has not been clinically staged for their cancer

• The subject has evidence of or is being treated for an active infection

• The subject cannot perform the appropriate follow-up or complete the study for whatever reason.

• The subject has not consented to an additional tumor biopsy and MRI after my seven days of treatment with methazolamide

• The subject has evidence of chronic obstructive pulmonary disease

• The subject is currently breastfeeding

• The subject is pregnant

• The subject takes aspirin chronically

• The subject has a history of Stevens-Johnson syndrome

• The subject has not signed the approved informed consent

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Drug:
• Methazolamide

• Cisplatin

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Irvine

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the feasibility in improving tumor oxygenation